Flag of the European Union EU Clinical Trials Register Help

Clinical trials for - Crohn’s Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28,503 result(s) found for: - Crohn’s Disease. Displaying page 892 of 1,426.
    «« First « Previous 888  889  890  891  892  893  894  895  896  Next» Last»»
    EudraCT Number: 2018-000783-29 Sponsor Protocol Number: GBR830-204 Start Date*: 2018-12-18
    Sponsor Name:Ichnos Sciences SA
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects with Moderate to Severe Atopic Dermatitis.
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-018006-21 Sponsor Protocol Number: 205.420 Start Date*: 2010-06-10
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase II, randomised, double- blind, placebo controlled, cross-over efficacy and safety comparison of tiotropium 5 μg administered once daily (in the evening) and tiotropium 2.5 μg administered t...
    Medical condition: moderate persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) EE (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001149-25 Sponsor Protocol Number: FSS-AS-301 Start Date*: 2014-11-07
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 12-Week, Double-Blinded, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/ Salmeterol Multidose Dry Powder Inhaler i...
    Medical condition: Persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-012057-38 Sponsor Protocol Number: CQTI571A2301 Start Date*: 2009-08-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arteria...
    Medical condition: Pulmonary arterial hypertension (PAH) patients who have a PVR ≥800 dynes.sec.cm-5 despite treatment with two or more specific PAH therapies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) ES (Completed) FR (Completed) SE (Completed) BE (Completed) IT (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003088-23 Sponsor Protocol Number: M13-099 Start Date*: 2012-12-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adults with Genotype 1 Chroni...
    Medical condition: Chronic Hepatitis C Infection and compensated cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002885-38 Sponsor Protocol Number: HGT-HIT-094 Start Date*: 2013-10-22
    Sponsor Name:Shire HGT Inc
    Full Title: A Controlled,Randomized,Two-arm,Open-label,Assessor-blinded,Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction with Elaprase® in Pediatric Patients with Hunter Syndrome and...
    Medical condition: Long-term treatment of Hunter syndrome and cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10056889 Mucopolysaccharidosis II PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001549-13 Sponsor Protocol Number: GB39242 Start Date*: 2016-12-16
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA
    Medical condition: Uncontrolled Severe Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10003560 Asthma NOS LLT
    19.0 100000004855 10015888 Extrinsic asthma LLT
    19.0 100000004855 10003561 Asthma, unspecified LLT
    19.0 100000004855 10001705 Allergic asthma LLT
    19.0 100000004855 10003554 Asthma aggravated LLT
    19.0 100000004855 10068393 Neutrophilic asthma LLT
    19.0 100000004855 10022847 Intrinsic asthma LLT
    19.0 100000004855 10074614 Nocturnal asthma LLT
    19.0 100000004855 10003638 Atopic asthma LLT
    19.0 100000004855 10068463 Paucigranulocytic asthma LLT
    19.0 100000004855 10009029 Chronic obstructive asthma (with obstructive pulmonary disease), w/o-ment of status asthmaticus LLT
    19.0 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-002785-10 Sponsor Protocol Number: 2005032 Start Date*: 2005-10-21
    Sponsor Name:Procter & Gamble Pharmaceuticals Inc
    Full Title: A Phase III, Multicenter, Double-Blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly with 5 mg Risedronate Daily in the Treatment of Pos...
    Medical condition: Osteoporosis in post-menopausal women
    Disease: Version SOC Term Classification Code Term Level
    7.0 10031285 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) FI (Completed) ES (Ongoing) EE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007659-15 Sponsor Protocol Number: NC-07-03 Start Date*: 2008-04-22
    Sponsor Name:Lumavita AG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Investigate the Efficacy, Safety, and Tolerability of 3 doses of SPK 0602 (pentamycin) Vaginal Tablets vs Placebo (veh...
    Medical condition: Symptomatic Vaginitis due to Bacterial Vaginosis, Candidiasis or Trichomoniasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062167 Vaginitis bacterial PT
    9.1 10046950 Vaginitis LLT
    9.1 10046958 Vaginitis trichomonal LLT
    9.1 10048238 Yeast vaginitis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed) DE (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014644-11 Sponsor Protocol Number: MSA-RAS-202 Start Date*: 2009-12-08
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy o...
    Medical condition: Multiple System Atrophy of the Parkinsonian Subtype
    Disease: Version SOC Term Classification Code Term Level
    12.0 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) HU (Completed) AT (Completed) NL (Completed) IT (Completed) PT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000410-20 Sponsor Protocol Number: C0168T72 Start Date*: 2007-08-13
    Sponsor Name:Centocor BV
    Full Title: A Phase 3, Randomized, Open-label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADE®) in Pediatric Subjects with Moderately to Severely Active Ulcerativ...
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045365 Ulcerative colitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-024371-12 Sponsor Protocol Number: CN162-010 Start Date*: 2011-11-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A multicenter, Double-blind 58 week Rollover Study to assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression.
    Medical condition: Subjects with Treatment Resistant Major Depression
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) SE (Completed) FI (Prematurely Ended) AT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002474-36 Sponsor Protocol Number: GS-US-218-0108 Start Date*: 2014-11-24
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT...
    Medical condition: Respiratory Syncytial Virus (RSV) Infection of the upper respiratory tract.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10039247 RSV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-016357-17 Sponsor Protocol Number: AI463-189 Start Date*: 2010-12-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) versus Placebo in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive Revised Pro...
    Medical condition: CHRONIC HEPATITIS B VIRUS,PEDIATRIC
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) GR (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019162-83 Sponsor Protocol Number: Y5252120148 Start Date*: 2011-06-07
    Sponsor Name:Ipsen Innovation
    Full Title: A phase III, multicentre, prospective, open label extension study to assess the long term safety and efficacy of repeated treatment of Dysport intramuscular injections used for the treatment of upp...
    Medical condition: Arm spasticity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10048970 Arm spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SK (Completed) PL (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-002715-28 Sponsor Protocol Number: NV27779 Start Date*: 2011-12-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH TELAPRE...
    Medical condition: Chronic Hepatitis C (CHC), Genotype 1
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000711-40 Sponsor Protocol Number: DIUR-005 Start Date*: 2015-11-19
    Sponsor Name:Diurnal Ltd
    Full Title: A Phase III study of efficacy, safety and tolerability of Chronocort® compared with standard glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia.
    Medical condition: Congenital adrenal hyperplasia (CAH); is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010323 Congenital adrenal hyperplasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-005326-19 Sponsor Protocol Number: NN9924-4234 Start Date*: 2016-09-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment. A 26-week randomised, double-blind, placebo-controlled trial
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019585-90 Sponsor Protocol Number: WV21913 Start Date*: 2011-05-05
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus®, in Com...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2005-000706-31 Sponsor Protocol Number: IMMU-103-04 Start Date*: 2005-05-13
    Sponsor Name:Immunomedics, Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    10042945
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prohibited by CA) BE (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 888  889  890  891  892  893  894  895  896  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 08:29:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA